Ad-REIC gene therapy: Promising results in a patient with metastatic CRPC following chemotherapy

Hiromi Kumon, Katsumi Sasaki, Yuichi Ariyoshi, Takuya Sadahira, Shin Ebara, Takao Hiraki, Susumu Kanazawa, Hiroyuki Yanai, Masami Watanabe, Yasutomo Nasu

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induc-tion of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalClinical Medicine Insights: Oncology
Publication statusPublished - Mar 23 2015


  • Cancer gene therapy
  • Cancer vaccine
  • Metastatic castrate-resistant prostate cancer
  • REIC/Dkk-3 gene

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Ad-REIC gene therapy: Promising results in a patient with metastatic CRPC following chemotherapy'. Together they form a unique fingerprint.

Cite this